haematologica the hematology journal

author contribution form

Title	Efficacy and safety of sildenafil for the treatment of severe pulmonary hypertension in patients with hemoglobinopathies: results from a long term follow-up
First author	Giorgio Derchi

According to the International Committee of Medical Journal Editors (ICMJE) (http://www.icmje.org/ethical_lauthor.html):

"Authorship credit should be based on: 1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; and 3) final approval of the version to be published. Authors should meet conditions 1, 2 and 3. Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship".

The responsible author(s) of this manuscript confirm(s) that all persons designated as authors qualify for authorship, and that each author has participated sufficiently in the work to take public responsibility for appropriate portions of the content.

Specific contributions of each author are listed on page 2 of this document.

Responsible author(s):

author(s) responsible for the integrity of the work as a whole

Name: Gian Luca Forni

Institute: Ente Ospedali Galliera

Hematology - Centre for Microcitemia and Congenital Anemias

e-mail: <u>gianluca.forni@galliera.it</u>

Author contributions (maximum 1 page):

Please describe the contributions of each author, indicating who was responsible for each part of the study and the preparation of the manuscript (collection of data, experiments, data analysis, generation of figures, collection of images, interpretation of data, preparation of the text, etc.)

GD, GLF: conception and design of the study, carrying out the human assessments, drafting the letter, acquisition, analysis and interpretation of data, final approval of the version to be published; MB, PB, GD'A, RL, RO, MDC: acquisition, analysis and interpretation of the data, revising the letter for important intellectual content, final approval of the version to be published.